Respiratory News and Research

RSS

Findings recommend expectant monitoring for women with gestational hypertension

In a study to be presented on Feb. 6 at 8:15 a.m. CST, at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting -, in New Orleans, researchers will report findings that recommend expectant monitoring instead of immediate delivery for women with gestational hypertension or preeclampsia between 34 and 37 weeks of pregnancy.

4 Feb 2014

URTI risk factor for chronic, recurrent otitis media

Results from a meta-analysis indicate that upper respiratory tract infection increases the odds of chronic or recurrent otitis media over sixfold.

3 Feb 2014

Parents of children with disabilities more likely to suffer from chronic health conditions

A University of Limerick study has found that parents of children with learning or developmental disabilities have an increased risk of depression and are more likely to suffer from chronic health conditions. The figures showed that 15% of parents of children with disabilities were classified as depressed and unfortunately less than half of them reported being treated for depression.

3 Feb 2014

VIB and CD3 sign agreement with AstraZeneca for development of novel MALT1 inhibitors

VIB and CD3 (KU Leuven) today announced the signing of a license and collaboration agreement with AstraZeneca for the development of novel MALT1 inhibitors as therapeutics in inflammatory and oncological diseases.

31 Jan 2014

Vanda Pharmaceuticals announces FDA approval of HETLIOZ for Non-24 treatment

Vanda Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration has approved HETLIOZ (tasimelteon) 20mg capsules for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). HETLIOZ is the first FDA approved medication for Non-24.

31 Jan 2014

Bubble CPAP device increases survival rate of newborns with severe respiratory illness

The first clinical study of a low-cost neonatal breathing system created by Rice University bioengineering students demonstrated that the device increased the survival rate of newborns with severe respiratory illness from 44 percent to 71 percent.

31 Jan 2014

CCSC identifies 5 routine practices for multidisciplinary teams of critical care professionals

The American Association of Critical-Care Nurses (AACN) — as part of the Critical Care Societies Collaborative (CCSC) — has identified five routine critical care practices that should be questioned because they may not always be necessary and could, in fact, be harmful.

29 Jan 2014

FDA approves Teva's sNDA for three-times-a-week COPAXONE 40mg/mL

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has approved the Company's supplemental new drug application for three-times-a-week COPAXONE 40mg/mL, a new dose of COPAXONE.

28 Jan 2014

FOB Synthesis enters into license agreement with AstraZeneca to treat drug-resistant bacterial infections

FOB Synthesis, Inc. has entered into a research and development option and license agreement with AstraZeneca for the development of a novel antibiotic to treat drug-resistant bacterial infections.

28 Jan 2014

S. pneumoniae predicts acute sinusitis microbial response

Research from the USA shows that confirmed nasopharyngeal colonization with Streptococcus pneumoniae independently predicts a rapid response to antimicrobial therapy in children with acute sinusitis.

27 Jan 2014

Active Biotech, Teva remain committed to NERVENTRA clinical development program for multiple sclerosis

Teva Pharmaceutical Industries Ltd. and Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today that both companies remain committed to the NERVENTRA® (laquinimod) clinical development program for multiple sclerosis (MS) following the announcement of a negative opinion for the treatment of relapsing-remitting multiple sclerosis (RRMS) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).

27 Jan 2014

E.R. expert warns public about 5 things doctor may do wrong when treating for flu

The flu season is in full swing starting mostly in the second week of January when emergency rooms are more busy than usual with patient with flu like symptoms. Dr. James Kojian, E.R. expert and founder of DRTOHELP.COM, warns the public about five things your doctor may be doing wrong when treating for the flu.

25 Jan 2014

NJHA honors several individuals and organizations for commitment to healthcare

Several individuals and organizations were honored today at the 95th Annual Meeting of the New Jersey Hospital Association at the Hyatt Regency Princeton.

24 Jan 2014

Many serious diseases come from the air that we breathe every day

At rest, we breathe approx. 12-15 times per minute, and for each inhalation we change approx. one litre of air. Depending on the activity level, this makes up a daily quantity in the order of twenty cubic metres of air that - with its content of pollution in the form of particles and different gases - can make us ill depending on how polluted the air is.

24 Jan 2014

Comprehensive supplement released on Thomas L. Petty Aspen Lung Conference

The Annals of the American Thoracic Society has released a comprehensive supplement on the 56th annual Thomas L. Petty Aspen Lung Conference entitled "The Lung Microbiome: A New Frontier in Pulmonary Medicine."

24 Jan 2014

Covidien announces financial results for first quarter of fiscal 2014

Covidien plc today announced financial results for the first quarter of fiscal 2014 (October - December 2013). First-quarter net sales of $2.64 billion increased 3% from the $2.57 billion in the first quarter a year ago. Operational sales growth in the quarter was 5%, as foreign exchange rate movement lowered the quarterly sales growth rate by two percentage points.

24 Jan 2014

NICE approves MabThera for treating severe forms of GPA and MPA

Today the National Institute for Health and Care Excellence has approved the use of MabThera for two potentially life-threatening auto-immune diseases, GPA and MPA, which result in the inflammation and damage of small blood vessels and frequently involve multiple organs. The two diseases affect over 13,000 people in the UK and are characterised by the breaking down of specific areas of tissue in the body that, if not treated, can lead to organ damage, organ failure and even death.

24 Jan 2014

Prosonix announces positive top-line results from PSX1002 Phase 2 study for COPD treatment

Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design, announces positive top-line results from its Phase 2 clinical study with PSX1002 in patients with moderate to severe chronic obstructive pulmonary disease.

23 Jan 2014

Home-based hospice practices for hospitalized patients could improve end-of-life care

A study by researchers at the Birmingham Veterans Affairs Medical Center and the University of Alabama at Birmingham says using home-based hospice practices for terminally ill, hospitalized patients could reduce suffering and improve end-of-life care.

23 Jan 2014

ECMO: A last-resort therapy for extremely severe cases of influenza

Physicians at the University of Alabama at Birmingham are employing a technology known as ECMO as a last-resort therapy for extremely severe cases of influenza. ECMO, short for extracorporeal membrane oxygenation, is a sort of portable heart/lung bypass machine.

23 Jan 2014

Respiratory News and Research

Findings recommend expectant monitoring for women with gestational hypertension

URTI risk factor for chronic, recurrent otitis media

Parents of children with disabilities more likely to suffer from chronic health conditions

VIB and CD3 sign agreement with AstraZeneca for development of novel MALT1 inhibitors

Vanda Pharmaceuticals announces FDA approval of HETLIOZ for Non-24 treatment

Bubble CPAP device increases survival rate of newborns with severe respiratory illness

CCSC identifies 5 routine practices for multidisciplinary teams of critical care professionals

FDA approves Teva's sNDA for three-times-a-week COPAXONE 40mg/mL

FOB Synthesis enters into license agreement with AstraZeneca to treat drug-resistant bacterial infections

S. pneumoniae predicts acute sinusitis microbial response

Active Biotech, Teva remain committed to NERVENTRA clinical development program for multiple sclerosis

E.R. expert warns public about 5 things doctor may do wrong when treating for flu

NJHA honors several individuals and organizations for commitment to healthcare

Many serious diseases come from the air that we breathe every day

Comprehensive supplement released on Thomas L. Petty Aspen Lung Conference

Covidien announces financial results for first quarter of fiscal 2014

NICE approves MabThera for treating severe forms of GPA and MPA

Prosonix announces positive top-line results from PSX1002 Phase 2 study for COPD treatment

Home-based hospice practices for hospitalized patients could improve end-of-life care

ECMO: A last-resort therapy for extremely severe cases of influenza

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News